ストックスクリーナーアプリを入手
60.13
0.52%
0.31
プレマーケット:
59.57
-0.56
-0.93%
前日終値:
$59.82
開ける：
$60.29
24時間の取引高:
1.49M
Relative Volume:
1.07
時価総額：
$8.65B
収益：
-
当期純損益:
$-507.65M
株価収益率:
-13.07
EPS:
-4.6
ネットキャッシュフロー:
$-616.24M
1週間 パフォーマンス:
-4.62%
1か月 パフォーマンス:
+8.77%
6か月 パフォーマンス:
+87.03%
1年 パフォーマンス:
-14.39%
1日の値動き範囲:
$59.11
$62.27
1週間の範囲:
$58.53
$62.73
52週間の値動き範囲:
$27.66
$76.61
Vaxcyte Inc Stock (PCVX) Company Profile
名前
Vaxcyte Inc
セクター
電話
650-837-0111
住所
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
60.13 | 8.61B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 繰り返されました | Needham | Buy |
| 2025-09-12 | 開始されました | Goldman | Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 開始されました | Goldman | Buy |
| 2023-12-07 | 開始されました | Mizuho | Buy |
| 2023-04-18 | 開始されました | TD Cowen | Outperform |
| 2023-01-03 | 繰り返されました | Needham | Buy |
| 2022-12-15 | 開始されました | Guggenheim | Buy |
| 2022-11-17 | 開始されました | BTIG Research | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-24 | 再開されました | Jefferies | Buy |
| 2020-07-07 | 開始されました | BofA Securities | Buy |
| 2020-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 開始されました | Needham | Buy |
すべてを表示
Vaxcyte Inc (PCVX) 最新ニュース
Vaxcyte (NASDAQ: PCVX) CTO reports stock awards and tax-related share disposals - Stock Titan
Vaxcyte (PCVX) CEO receives large RSU and option grants, surrenders shares for tax - Stock Titan
Vaxcyte Earnings Call: Cash Strength, Trials Accelerate - TipRanks
Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte’s VAX-31 Shift the Bull Case (PCVX)? - Yahoo Finance
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. - inkl
Vaxcyte, Inc. (PCVX) - DirectorsTalk Interviews
Vaxcyte, Inc. $PCVX Shares Sold by TD Asset Management Inc - MarketBeat
Vaxcyte Advances VAX-31 Toward Phase 3 As Valuation Gap Persists - Yahoo Finance
A Look At Vaxcyte (PCVX) Valuation As Share Price Momentum Rebuilds - Yahoo Finance
Citigroup Inc. Sells 116,206 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
PCVX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Vaxcyte (PCVX) Valuation After Recent Share Price Volatility - simplywall.st
Analysts’ Top Healthcare Picks: Vaxcyte (PCVX), TransMedics Group (TMDX) - The Globe and Mail
Westfield Capital Management Co. LP Purchases 663,817 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vanguard Group Inc. Has $443.78 Million Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte (PCVX): BTIG Raises Price Target, Maintains Buy Rating | - GuruFocus
JPMorgan Chase & Co. Has $56.37 Million Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans - TipRanks
BTIG raises Vaxcyte price target to $89 on vaccine breadth edge - Investing.com Nigeria
Vaxcyte (NASDAQ:PCVX) Shares Gap Down Following Weak Earnings - MarketBeat
Leerink raises Vaxcyte stock price target on vaccine pipeline expansion By Investing.com - Investing.com Canada
Leerink raises Vaxcyte stock price target on vaccine pipeline expansion - Investing.com Nigeria
Vaxcyte, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Highlights: Unprecedented Phase 2 Results and ... By GuruFocus - Investing.com Canada
Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight - GuruFocus
Vaxcyte Q4 Earnings Call Highlights - MarketBeat
Vaxcyte (NASDAQ:PCVX) Issues Quarterly Earnings Results - MarketBeat
Vaxcyte Q4 2025 Earnings Call Transcript - MarketBeat
Vaxcyte Launches New $500 Million ATM Equity Program - TipRanks
PCVX: VAX-31 advanced in late-stage trials, with strong financials and manufacturing readiness for 2026 - TradingView
Vaxcyte enters into sales agreement, may sell shares of common stock of up to $500 million - marketscreener.com
Vaxcyte Enters Into Sales Agreement, May Sell Shares Of Common Stock Of Up To $500 Million - TradingView
Vaxcyte Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Vaxcyte Q4 Loss Widens - marketscreener.com
Vaxcyte (NASDAQ: PCVX) launches $500M common stock sales plan - Stock Titan
Vaxcyte (PCVX) Advances Pneumococcal Vaccine Programs Towards Re - GuruFocus
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
All eyes on Vaxcyte earnings as pneumococcal vaccine nears pivotal data By Investing.com - Investing.com India
All eyes on Vaxcyte earnings as pneumococcal vaccine nears pivotal data - Investing.com Australia
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a 74% Potential Upside in the Innovative Vaccine Sector - DirectorsTalk Interviews
Earnings Outlook For Vaxcyte - Benzinga
Aug Movers: Whats the RSI of Vaxcyte Inc stockRisk Management & Safe Entry Trade Signal Reports - baoquankhu1.vn
Volume Report: Is Vaxcyte Inc affected by consumer sentiment2025 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Patterns Watch: What makes UDMY stock attractive todayAnalyst Upgrade & AI Powered Market Entry Strategies - baoquankhu1.vn
Aug Retail: What hedge funds are buying MFS High Yield Municipal TrustDividend Hike & AI Powered Market Trend Analysis - baoquankhu1.vn
Hedge Fund Bets: What is the earnings history of Otter Tail Corporation2025 Technical Patterns & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Technical Analysis: Is PSMT a defensive stockPrice Action & Daily Volume Surge Signals - baoquankhu1.vn
Vaxcyte’s VAX-31 Moves Into Phase 3: What This Pneumococcal Vaccine Update Means for PCVX Investors - TipRanks
Vaxcyte shows market leadership with jump to 85 RS rating - MSN
Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials - Finviz
Vaxcyte Inc (PCVX) 財務データ
収益
当期純利益
現金流量
EPS
Vaxcyte Inc (PCVX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Dhaliwal Harpreet S. | Chief Technical Ops Officer |
Dec 31 '25 |
Sale |
46.69 |
9,743 |
454,891 |
23,928 |
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):